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Abstract The formation of new blood vessels, angiogenesis, is a highly-regulated
active process that is critical for the development of the normal and malignant
prostate. The vascular endothelial growth factor (VEGF) system assumes a critical
role in the angiogenic process. Angiogenesis is a prerequisite for the expansion of
solid tumours beyond 1e3 mm3 and is stimulated in response to a hypoxic
environment. This review discusses the process of angiogenesis and the key
angiogenic mediator, VEGF, and their role in tumour progression and metastasis. A
better understanding of the mechanisms behind angiogenesis will ultimately lead to
the development of new anti-angiogenic agents in the management of prostate
cancer.
ª 2005 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Prostate cancer is the most commonly diagnosed
male malignancy in Europe and the USA. In Europe
more than 10,000 men are found to have prostate
cancer and 35,000 men die from the disease per
year.1,2 Prostate cancer is likely to achieve an
even greater incidence as populations continue to
age and the mortality from other diseases de-
creases.
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doi:10.1016/j.ijsu.2005.03.013New vasculature is recruited from pre-existing
vessels by a process called angiogenesis,3 and it is
particularly relevant to the pathology of virtually
all human tumours.4 Developing tumours require
new vasculature as they grow in order to ensure
a constant supply of nutrients and oxygen and to
allow for the elimination of metabolic waste.4
Choy and Rafii5 suggested that angiogenesis is also
a prerequisite for tumour progression. The angio-
genic process in solid tumours is crucial for
advanced tumour growth6 and progression to
a metastatic state.7 It has been proposed that
microvessel density (MVD) is an indicator of bi-
ological aggressiveness and metastatic potential in
many primary tumours.8ublished by Elsevier Ltd. All rights reserved.
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ment the effects of chemotherapy and radiation
by limiting the tumour to a dormant state of low
metastatic potential9; hence, interest in anti-
angiogenic therapies has increased dramatically.10
Angiogenesis is initiated in quiescent endothelial
cells following a shift in the balance between
endogenous angiogenesis-inhibitory factors and
angiogenesis-promoting factors4 (Table 1). A shift
in the equilibrium to a pro-angiogenic state occurs
at an early to mid-stage in tumour development.
This leads to activation of an ‘angiogenic switch’
and, consequently, the formation of new vascula-
ture.11 Growth factors up-regulated during angio-
genesis, in particular basic fibroblast growth factor
(bFGF)12 and VEGF,13 have been identified and may
also be important as therapeutic targets and/or
molecular indicators of disease stage. Raised levels
of VEGF are produced in the malignant prostate
compared to benign prostatic hyperplasia.14 VEGF
is a key mediator of both normal and abnormal
angiogenesis due to its capacity to stimulate
virtually every step in the angiogenic process.15,16
VEGF expression in human prostate stroma can be
stimulated by androgens, thus supporting the
hypothesis that androgen ablation affects prostate
tumours through the inhibition of angiogenesis.5
Angiogenesis
Blood vessels are endothelial-lined tubes that
provide tissues with oxygen and nutrients and
remove their metabolic waste products while alsoproducing a spectrum of growth factors (Table 1)
with paracrine effects on surrounding cells. Thus
these vessels may support both normal and malig-
nant tissue growth by providing a sufficient blood
supply and by secreting growth factors.
The mechanism of angiogenesis (Fig. 1)
The growth of new capillaries from existing blood
vessels is a complex multi-step process involving
extracellular matrix components. It begins with an
enlargement of the parent vessel, which then
sprouts or divides by intussusception or bridging,
and subsequently splits into individual capillar-
ies.17 By far the most common, sprouting angio-
genesis, involves activation, migration and
proliferation of endothelial cells, which ultimately
assemble into solid cords that acquire a lumen and
attach to existing vessels.17 The process of angio-
genesis includes a maturation phase where peri-
endothelial cells, such as smooth muscle cells and
pericytes, encapsulate and stabilise the vessel by
inhibiting endothelial cell proliferation and
migration and enhance the formation and pro-
duction of extracellular matrix.18 Whether angio-
genesis occurs by sprouting, intussusception, or
bridging, the above process protects new vessels
from rupture and regression as well as endowing
vessels with the viscoelastic and vasomotor prop-
erties necessary to accommodate changing needs
in tissue perfusion.17
The angiogenic process is usually tightly con-
trolled (i.e. turned on for a short period and thenTable 1 Angiogenic factors in prostate cancer
Route Pro-angiogenic Anti-angiogenic
Exogenous agents Linomide
Carboxyamido-triazole
Neutralizing antibodies
Fumagillin analogue
MMP inhibitors
COX-2 inhibitors
Endogenous agents Matrix metalloproteinases (MMPs) Tissue inhibitor of metalloproteinase 1 (TIMP-1)
VEGF Interleukin-10 (IL-10)
Basic fibroblast growth factor 2 (bFGF-2) Angiostatin
Fibroblast growth factor 4 (FGF-4) Endostatin
Transforming growth factor b1 (TGF- b1) Prostate-specific antigen (PSA)
Interleukin 8 (IL-8) Interferon (IFN)
Interleukin 6 (IL-6)
Interleukin 1b (IL-1b)
Cyclooxygenase 2 (COX-2)
Nitric Oxide (NO)
Tumour necrosis factor (TNF), Insulin
growth factor 1 (IGF-1)
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uncontrolled angiogenesis can contribute to sev-
eral pathological processes such as, rheumatoid
arthritis, diabetic retinopathy and neoplastic
growth.
VEGF expression correlates with malignant
potential in the prostate
The malignant potential of prostate tumours is
correlated to VEGF expression with aggressive
tumours expressing higher levels of VEGF.20 In
mice models, when the activity of VEGF is blocked
by antibodies or receptor signalling inhibitors,
decreased vascularisation, suppression of tumour
growth, and metastasis results.21 VEGF expression
in tumours, just as in normal prostate tissue, also
appears to be regulated by androgens.22 A positive
correlation has been found between VEGF expres-
sion and vascular density.23 Immunohistochemical
techniques (IHC) used by Ferrer et al.24 demon-
strated that human prostate cancer cells stained
positively for VEGF and correlated with micro-
vessel density (MVD). They also found that benign
prostatic hyperplasia (BPH) and normal prostate
cells display little VEGF staining and vascularity.14
Haggstrom et al.20 demonstrated that VEGF ex-
pression is associated with metastatic capability,
by enhancing the hyperpermeability of vessels,
endothelial cell proliferation, and endothelial cell
migration. In Dunning tumours in rats, VEGF mRNA
and serum protein are highest in metastatic sub-
lines in comparison with the non-metastatic sub-
line.20 Duque et al.25 also demonstrated that
plasma and urine VEGF levels are higher in patients
with metastatic prostate cancer than in patientswith localized disease or healthy controls. Salven
et al.26 also showed that circulating VEGF is higher
in patients with disseminated cancer than in the
normal population. A randomized controlled trial
in hormone refractory patients found that low pre-
treatment urine VEGF levels were predictive of
improved survival27; furthermore, Jose et al.28
demonstrated that patients with plasma VEGF
levels greater than 18 pg/ml were 10 times more
likely to have metastases and that patients with
PSA levels greater than 20 ng/mL had significantly
higher VEGF levels than patients with PSA levels
less than 20 ng/mL. They also found a trend for
VEGF to be higher in patients with high Gleason
sums (8e10).28
Hypoxia stimulates tumour angiogenesis
The rapid growth of cancerous cells within a tu-
mour is seldom complemented by the develop-
ment of vascularisation sufficient to support the
growing tumour mass; hence most human tumours
encounter hypoxia early in their development.29
This event is potentially advantageous to the
patient as tumour cells starved of oxygen are much
less likely to multiply and are increasingly liable to
undergo apoptosis. The tumour’s inability to at-
tract and develop a blood supply makes more likely
to remain dormant.30 However, the activation of
a tumour hypoxic-response system alters its me-
tabolism, improving survivability under low-oxygen
conditions and increasing its angiogenic potential
by upregulating the production of critical angio-
genic factors, particularly VEGF31 (Fig. 2), thereby
improving the tumour’s potential for attractingStage 1 
Resting Blood Vessel 
Stage 2
Degradation of the basement membrane
Stage 3
Leakage of plasma proteins and the
formation of the provisional matrix with
migration and proliferation 
Stage 5
Restoring endothelial cell junctions 
Stage 4 
Reorganisation of the vessel 
Figure 1 A diagram to show the different stages of angiogenesis.
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giogenesis ‘switches’ the tumour fromaprevascular
(dormant) to a vascular (exponential growth)
phase.19
HIF1a protein has been found to be over-
expressed in 13 of 19 different solid tumour types,
including prostate cancer.32 Zhong et al.32 demon-
strated HIF1a positivity in nine out of 11 prostate
cancer specimens examined, while none was seen
in benign tissue specimens. The authors also
correlated HIF1a expression with both uncharac-
teristic p53 growth and increased cell proliferation
activity in the tumours. Salnikow et al.33 tested
the functional activity of HIF-1 in human prostate
cell lines from normal epithelial cells (PrEC),
hormone dependent LNCaP, hormone-independent
DU-145 and PC-3, and highly metastatic PC-3M
cancer cells. The authors demonstrated that HIF-1-
stimulated transcription and protein expression
was lowest in the PrEC (normal epithelial cell)
and LNCaP (hormone dependent) cells, and highest
in the PC-3M cells (highly metastatic). Given also
that high HIF-1 expression correlates with loss
of p53 function and desensitization to p21 in-
hibition, it is reasonable to conclude that a hypoxic
phenotype is associated with aggressive cancer
behaviour.33Huss et al.34 performed IHC and in situ analyses
of tissue specimens using a transgenic mouse
model to investigate the relationship between
HIF-1, VEGF, and angiogenesis. They suggested
that there were two distinct angiogenic events
involved in the development and progression of
prostate cancer. The first angiogenic ‘‘initiation
switch’’ is associated with increased expression of
HIF-1 and VEGF receptor plus recruitment and
amplification of intraductal vasculature.34 The
second angiogenic ‘‘progression switch’’ is associ-
ated with an increased level of expression of VEGF
protein in prostatic tissues as well as in the sera of
mice harbouring advanced, poorly differentiated,
and androgen-independent tumours.34 This implies
that the abnormally raised expression of HIF-1
protein in prostate tumour cells may have the
ability to make these cells more aggressive via
mechanisms of both androgen resistance and an-
giogenesis promotion. Increased levels of hypoxia,
as measured in patients, are directly correlated
with raised levels of expression of VEGF.35 There
are many interacting mechanisms for this relation-
ship. For example, HIF-1 binding to fms-like tyro-
sine kinase-1 and fetal liver kinase 1 is known to
induce VEGF expression.36 Studies have also
shown that in cancer cell lines, HIF-1 expression isHypoxia- response mechanism
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Figure 2 The hypoxia-response mechanism in the development of prostate cancer.
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transduction pathway, thus resulting in enhanced
VEGF production.37 This implies that, in addition to
hypoxia, mutations in the tumour suppressor gene
PTEN could contribute to the increased VEGF
expression observed in patients. Cvetkovic et al.38
proposed that prostate tumour cells adapt to de-
creased pO2 levels by transcription of HIF-1, which
causes VEGF production, ultimately leading to an
enhanced angiogenesis with its consequent effects
on the growth and the spread of such tumours.
Nitric oxide, cytokines, and growth factors
can also regulate VEGF
As well as hypoxia, VEGF is regulated by many
growth factors and cytokines at pre-transcrip-
tional,39 transcriptional,40 and post-transcriptional
levels.41 Fidler42 suggested that those molecules
that do not stimulate angiogenesis directly can
modulate angiogenesis by altering VEGF expression
in specific cell types and exerting indirect angio-
genic or anti-angiogenic effects. Molecules that
can initiate VEGF production include fibroblast
growth factor 2 (FGF-2),43 FGF-4,44 platelet de-
rived growth factor (PDGF),45 tumour necrosis
factor (TNF),46 transforming growth factor
b (TGF-b),47 insulin growth factor-1 (IGF-1)48 and
IL-6.49
Nitric oxide (NO) and VEGF up-regulate each
other’s production via a positive feedback loop
mechanism.50 NO contributes to the blood vessel
permeability effect of VEGF and VEGF-stimulated
vasodilatation. Uotila et al.51 found that NO syn-
thetase-2 has an elevated expression in both
prostate cancer and prostate intraepithelial neo-
plasia (PIN) compared to normal prostate tissue.
The VEGFR-2 can be up-regulated by VEGF in an
autocrine and/or paracrine mechanism and it has
also been suggested that VEGF autocrine stimula-
tion may coincide with progression to a malignant
phenotype.52,53
Recently, ras, raf, and src gene products have
been implicated as signalling intermediates in the
induction of VEGF transcription.54 The enhanced
expression of the activated forms of these genes is
accompanied by marked elevation of both VEGF
mRNA.55 VEGF expression is critical for ras-medi-
ated tumorigenesis, while loss of expression causes
dramatic decrease in vascular density and vascular
permeability as well as an increase in tumour cell
apoptosis.56 ras, raf and src activating mutations
are unusual in human prostate cancer, but may be
major signalling molecules by which circuits can be
corrupted.57 Any factor that stimulates ras-, raf-,and src-mediated signalling pathways may facili-
tate tumour angiogenesis via VEGF induction.
Conclusion
Angiogenesis is the key process in the development
of tumour vasculature for virtually all solid malig-
nancies including prostate cancer. It is a complex
process with many stimulatory and inhibitory
factors, most importantly VEGF, linked together
in poorly defined pathways. Anti-angiogenic ther-
apies (e.g. angiostatin inducers, VEGF inhibitors,
and cyclo-oxygenase inhibitors) have been found
to be successful in animal and cell line models, and
are currently under investigation in phase 2 clin-
ical trials. These molecules are being evaluated for
both efficacy and their toxicity profiles. As angio-
genesis is involved at a very early stage in prostate
tumour development, such strategies may prove
useful in the management of early disease. Pros-
tate cancer has a well defined pre-neoplastic stage
and it may be that anti-angiogenic strategies will
be employed in individuals with high-grade PIN in
an attempt to prevent the development of invasive
carcinoma. As the management of high-grade PIN
is currently highly controversial with no definite
successful strategy, such chemopreventive thera-
pies are badly needed.
Tumour cell hypoxia, via HIF-1, appears to be
a crucial stimulant for the angiogenic process to
allow tumour growth beyond a few millimetres as
well as the development of metastasis. Although
the tumour hypoxia response mechanism leads to
a multitude of downstream effects, it is angio-
genesis that is most crucial and also most suscep-
tible to molecular manipulation. Hence specific
attempts to develop targets for hypoxia have
been superseded by the development of anti-
angiogenic molecules. Improved understanding of
the molecular mechanisms involved in angiogene-
sis and tumour hypoxia-response will allow for
future targeted therapies to be developed that
may, either alone or in combination with estab-
lished modalities like chemotherapy, surgery, and
radiotherapy, provide improved cure and control
rates over current therapeutic strategies. Such
combination strategies are currently the subject
of various clinical phase 2 trials in colorectal and
breast cancer. Once these trials plus those in-
vestigating the biological effect of anti-angiogenic
therapies in prostate cancer report, further trials
investigating chemoprevention in high-grade PIN
patients as well as the use of combination treat-
ments in those with established disease can be
advocated.
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